Please login to the form below

Not currently logged in
Email:
Password:

Pfizer’s Alan Maine moves to Edelman

He joins the communications firm as its senior director

Alan MaineGlobal communications and marketing firm Edelman has strengthened its health public affairs capabilities with the addition of Alan Maine, who joins as its senior director.

Maine, who previously served as head of policy and public affairs at Pfizer UK, was responsible for government affairs and market access policy development activity, covering both corporate and therapy area public affairs.

During his time at Pfizer, Maine also worked with industry associations on campaigns, policies and initiatives relating to access to medicines.

He said: “I am delighted to be working with such a forward-looking company as Edelman and I am thrilled to work with the team to deliver innovative and strategic campaigns.”

Prior to his time with Pfizer, Maine was head of government affairs at Wyeth Pharmaceuticals - later acquired by Pfizer - and has held other roles with Merck Sharpe & Dohme.

Kate Hawker, managing director for Edelman UK, said: “We are very excited about Alan joining Edelman as he brings with him such great knowledge and insight of the complex challenges in the UK.”

5th February 2018

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...